December 11, 2018
The winds of volatility remain
News: I am missing the “Viagra” of share pricing, company announcements of clinical data success
I answer one question, in which company should investors put, keep and commit their money!
In compiling my indication signals, specific knowledge of the sector and its practices as to lessons learned. It’s important for investors to identify and determine which indication is actually performance based.
December 7, 2018
GBT is down -$2.90% or -6.21% to $43.77
December 11, 2018
As my constructed coverage of 45 companies closes neutral with an Advance/Decline Line (A/DL) of 21/21 and 3 flats
There is just NO trust to the long side as short positions continue to rise as volume remains low with continuous volatility
Out and about: Does Biostage (BSTG - $0.49 or -16.34%) have interlocking financial interests and conflicts with a director, scientific advisor and the medical institution where research is taking place and where trials are to take place?
Investors should be reading about today’s final “figures” – be a subscriber and be ready for tomorrow’s session! As I have stated … today’s gold could be tomorrow’s tin!
December 7, 2018
GBT is down -$2.90% or -6.21% to $43.77
November 23, 2018
Q3/18 financial results is a scorecard of (AKA) earnings of 45 covered companies 37 of 45 by 11/23 The current LPS (loss per share) or net income, cash positio, "runways" and correlation of "street" expectations - it's a reflection of this universe's investing "status" Investors can gauge the financial health versus the scientific opportunity and whether or not it deserves their investment.
November 9, 2018
Post reporting their Q’s; snapshots of LPS (loss-per-share) and net incomes - follow the bouncing share prices … A breakdown of reporting “figures” and commentary including Thursday’s closing numbers,: Adverum Biotechnologies (ADVM +$0.05), Histogenics (HSGX +$0.01), BioTime (NTSEMKT: BTX -$0.11), Applied Genetic Technologies (AGTC +$0.21), Intrexon (XON -$0.12), BioLife Solutions (BLFS +$0.16), Caladrius Bioscience (CLBS +$0.32), Pluristem (PSTI -$0.01), Sangamo Therapeutics (SGMO -$0.58), Stemline Therapeutics (STML -$0.36), Organovo Holdings (ONVO) and Biostage (BSTG -$0.10) Ben Graham used to talk about the stock market being a cross between a voting machine and a weighing machine The market is still voting on Friday ...
The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.
© 2018 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
